I suspect that most preferred income investors are conservative by nature. I am. I don't believe I have any special talent or gift for trading, a crystal ball, or any access to insider information. Consequently, I have little expectation of prospering by consistently buying low and selling high. In fact, prior to becoming a fixed income investor, my trading history boasted the opposite, buying high and selling low. Tis sad but true, over those years, I've given more to the market than I've taken from it. However, that's yesterday's news, and of no real interest. Of importance is that I'm patient, analytical, organized, pretty good at math, and always looking for that angle, strategy, or edge to help guarantee my market success. The Art & Science of Preferred Dividend Investing details my history, education and growth as a preferred investor and the lessons I learned along the way. I want to share that knowledge by introducing you to this effective, profitable, and safe way to invest in preferred equities.
Mr. Rosenman has nearly 15-years executive experience in the health and wellness sectors, including weight loss, cosmetics skincare and nutrition, both Rx and OTC. Expertise areas include strategic market and product planning and corporate development (evaluation, recommendation and execution of strategic alliances and acquisitions). A MBA graduate of the Sweigart School of Business at Rider University, Rosenman devotes a portion of time back to the collegiate community as a graduate-level adjunct professor for healthcare marketing, consumer behavior and strategic planning. He has several published works in the field of U.S health and wellness, including a focus on how nutritional ingredients will transition into Rx space, specifically with lipid and herbal managment. His current professional role is with one of the fastest growing nutritional companies in the U.S., which also produces Rx and OTC products. He has served as an advisory board member to various organizations in the healthcare field, from venture start-ups to top global enterprises. Mr. Rosenman is a Senior Advisor with Guidepoint Global and is called upon by large institutional investors for insight and expert opinion on healthcare market opportunities (to date he has advised on more than $2 billion USD of related transactions/funding).
I am the VP of Monetization at Harvest (www.hvst.com). My role here is to ensure that Harvest is maximizing its monetization opportunities while maintaining the highest level of experience for our users, and advertisers.
George Moriarty is Executive Editor and VP Content at Seeking Alpha. He joined the company in January 2012 as Managing Editor of Opinion & Analysis and works closely with CEO Eli Hoffmann and other company leaders on content and publishing initiatives for the Seeking Alpha contributor community. George has worked as a financial journalist and editor since 1997, most recently as Editor-in-Chief at Merrill Lynch Wealth Management Online Platforms. Prior to Merrill, he was Executive Editor at TheStreet.com. He lives in Bucks County, PA, with his wife, four young children and one dog. Please contact him via direct message.
Research scientist and engineer who likes to play the deep fundamentals that really drive marketplace success in the long term. High interest in development biotechs as way to both profit and improve the world...